scholarly journals Academic Challenges and Concerns for Children with Sickle Cell Disease: Analysis of a Hospital-Based School Intervention Program

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 2165-2165
Author(s):  
Kristine Anne Karkoska ◽  
Kenneth Haber ◽  
Patrick T. McGann

Introduction: Neurocognitive deficits are a well-known complication in patients with sickle cell disease (SCD) and are often associated with overt stroke and silent infarctions. However, cognitive deficits may be seen in patients even without apparent MRI findings as compared to non-affected controls. Studies have also shown the impact of socioeconomic status and parental education on school retention and cognition in patients with SCD. More specifically, rates of retention and special education service use through either an Individualized Education Plan (IEP, providing specialized education services) or 504 Plan (providing accommodations due to physical disability/medical diagnosis) are reported as high as 40%. However, these historical data have been limited to primarily adolescent patients. Thus, a more thorough analysis is needed to better determine the prevalence and types of academic challenges among children with sickle cell disease, particularly younger ages. Methods: The Cincinnati Children's Hospital Medical Center's Comprehensive Sickle Cell Clinic includes a school intervention program. This program includes 1-2 full time school teachers who engage directly with patients, parents, and school staff to ensure the provision of adequate school-based services and to address specific challenges or concerns. Children with SCD are referred to the school interventionist by the clinical team (including both medical and psychosocial providers) for any school-related concern. The interventionist completes the Brief School Needs Inventory (BSNI), a thirty-item tool that determines a patient's educational risk based on academic and psychosocial history and parental responses. The BSNI provides a numeric score from 0-20 and a categorical risk of 1 (low risk) to 3 (high risk). In this retrospective review, the BSNI for all patients with SCD completed during the 2018-2019 school year were reviewed. The prevalence of the receipt of special education services (SES), grade retention, neuropsychological testing, and number of school absences were captured. Basic demographic and disease-related data, including zip code, patients' disease history, use of disease-modifying therapy, and any notable brain MRI findings were also recorded. Median household income was extrapolated from the zip codes based on 2017 US Census Bureau reporting (the most recently published year). Results: A total of 78 patients (58 HbSS, 17 HbSC, 3 HbS/β+-thalassemia) completed the BSNI for the 2018-19 academic year; an additional 15 children were also referred but did not complete the evaluation. Nearly all (95%) of patients with HbSS were receiving disease-modifying therapy (hydroxyurea or transfusions); 41% of patients with MRIs showed abnormal findings. Median age was 9 years (range 14 months - 19 years, preschool - post-secondary education). Nineteen percent of patients lived in a zip code with a median household income below the federal poverty level ($25,750). The mean BSNI score was 7.6±5.5; 27 patients were deemed low risk, 32 moderate risk, and 19 high academic risk by the BSNI (Table 1). A majority (50%) of parents responded with concerns both with obtaining support/accommodations for their child and explaining their child's medical needs to the school. Of 59 recorded, 24% of patients had had at least 16 absences in the prior year. Despite the diagnosis of SCD for all patients, only 21% had established 504 medical plans. Academic concerns were common with 20% of referred children reporting an IEP, 14% of patients with a history of grade retention, and an additional 10% with concerns for possible retention. Conclusion: The prevalence of academic difficulties and challenges is high amongst patients with SCD even in the elementary to middle school years, with rates of grade retention ~20% as compared to the national average of <2-6%. Parents of children with SCD report their greatest concerns as obtaining accommodations for their child and explaining their child's medical needs to school personnel. Most parents and schools are inadequately prepared or resourced to identify and address academic and medical needs in the school-based setting, resulting in persistent academic struggles for many children with SCD. A school intervention program is a feasible way to facilitate interaction between parents and schools to optimize educational experiences and outcomes. Disclosures No relevant conflicts of interest to declare.

2017 ◽  
Vol 34 (3) ◽  
pp. 355-366 ◽  
Author(s):  
Christyne Gomes Toledo de OLIVEIRA ◽  
Sônia Regina Fiorim ENUMO ◽  
Kely Maria Pereira de PAULA

Abstract Pain is common in Sickle Cell Disease. This study proposes a Psychological Intervention Program for Children with Sickle Cell Disease (Intervenção Psicológica para Crianças com Anemia Falciforme). It was applied to seven children in a hospital. The intervention was based in the Motivational Theory of Coping and includes the Coping with Pain Game (Jogo “Enfrentando a Dor”). The Computerized Assessment Instrument of Coping with Hospitalization-Pain (Instrumento Computadorizado para Avaliação do Enfrentamento da Hospitalização-Dor) was applied before and after seven weekly sessions. The results showed significant increase in the facilitating behaviors to cope with pain, and in problem-solving, an adaptive coping; and a reduction in the non-facilitating behaviors and in rumination, a maladaptive coping. The stressor perception as a challenge to the need of competence increased, whereas the stressor perception as a threat to the need of competence and autonomy decreased. This intervention may have contributed to promote adaptive coping with pain.


Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 856-856 ◽  
Author(s):  
Mandy David ◽  
Christopher Carroll ◽  
Ashley Lauriello ◽  
Benjamin Salzberg ◽  
Sophie Lanzkron

Abstract Background: The management of pain in adults with sickle cell disease (SCD) is complex, with the intermingling of both acute vaso-occlusive events and chronic daily pain. Sixty percent of adults with SCD suffer with every day chronic pain. In patients with frequent acute visits we use aggressive disease modifying therapy to decrease the risk of VOC yet there remains a subset of patients who continue to have frequent acute visits for pain. In addition, there are patients maintained on high doses of oral opioids as outpatients who continue to have high levels of daily pain. There is little data that escalating doses of opioids is associated with benefit, yet significant data to support that higher doses are associated with harms. We consider these to be cases of opioid failure. Identifying therapies for these patients that improve quality of life is essential. Buprenorphine is a partial mu opioid receptor agonist and kappa antagonist, and has a very high affinity for the mu receptors, with an elimination half-life of 28-37 hours for the sublingual administration. The reduced risk of overdose, lower risk for misuse, diminished withdrawal symptoms, and blunting of opioid craving make it an appealing alternative to full opioid agonists in a subset of patients with SCD who continue to have significant pain or are unable to wean off of ineffective opioid therapy. The purpose of this report is to describe our experience converting patients with SCD and chronic pain from chronic opioid therapy to buprenorphine. Methods: Routine clinical care in our clinic includes offering buprenorphine transition to patients on chronic opioid therapy with numerous acute care visits despite the use of disease modifying therapy; or patients on chronic opioid therapy reporting significant ongoing pain. Patients are typically weaned to lower opioid doses (goal 90 oral morphine equivalents) prior to the planned induction with buprenorphine. Once patients are at the goal dose, they are asked to hold opioids for 12-24 hours prior to presentation so that they are in at least mild opioid withdrawal prior to their first dose of buprenorphine to avoid precipitated withdrawal. The patient is assessed with the Clinical Opiate Withdrawal Scale (COWs) and if their score is 5 or higher they are administered their first dose of sublingual buprenorphine. If COWs scores are less than 5, buprenorphine is not initiated and the subject is asked to return the following day or earlier if withdrawal symptoms begin. Patients are reassessed with the COWs and dosed with buprenorphine hourly until withdrawal has ceased. The dose needed to minimize withdrawal is considered the working total daily dose. Patients are sent home and return the next day to start their once daily dose of buprenorphine. Urine toxicology testing is done the day of planned induction. Data on acute visits 6 months prior and 6 months post induction and on complications associated with induction were pulled from the electronic health record. Results: 21 patients have been converted from full agonist opioids to buprenorphine from 3/2015-6/1/2018. The average age of the patients at the time of induction was 36.1 years (SD 9.1), 62% were female. Sixteen (76 %) of the patients had sickle cell anemia, the remainder had variant genotypes. The mean dose (in morphine equivalents) of full agonist opioid that patients were on prior to weaning of opioids was 196.8 mg (SD 222.7) and just prior to induction was 85 mg (SD 70 mg) with a range of 11.4 to 315 mg. Seventeen patients tolerated the induction without any complications, 2 patients had abdominal cramps but were successfully converted, 2 patients has adverse reactions (1 had numbness of tongue and 1 with worsening of asthma) and buprenorphine was stopped. Of the 19 patients successfully converted, two chose to stop buprenorphine and resume taking full opioid agonists. For the 13 patients with 6 months of follow-up post induction, the median number of acute care visits prior to induction was 12.5 and post was 4.0 (Figure). Conclusions: Adults with sickle cell disease on chronic full agonist opioid therapy can be safely converted to buprenorphine. Acute care utilization has dropped significantly for patients post induction. Assessment of patient reported outcomes such as quality of life and pain interference are being collected. Buprenorphine appears to be a safe and effective medication in the management of pain in adults with SCD. Figure. Figure. Disclosures Lanzkron: PCORI: Research Funding; GBT: Research Funding; Prolong: Research Funding; Pfizer: Research Funding; selexys: Research Funding; NHLBI: Research Funding; HRSA: Research Funding; Ironwood: Research Funding.


BMJ Open ◽  
2021 ◽  
Vol 11 (11) ◽  
pp. e050880
Author(s):  
Matthew P Smeltzer ◽  
Kristen E Howell ◽  
Marsha Treadwell ◽  
Liliana Preiss ◽  
Allison A King ◽  
...  

ObjectivesSickle cell disease (SCD) leads to chronic and acute complications that require specialised care to manage symptoms and optimise clinical results. The National Heart Lung and Blood Institute (NHLBI) evidence-based guidelines assist providers in caring for individuals with SCD, but adoption of these guidelines by providers has not been optimal. The objective of this study was to identify barriers to treating individuals with SCD.MethodsThe SCD Implementation Consortium aimed to investigate the perception and level of comfort of providers regarding evidence-based care by surveying providers in the regions of six clinical centres across the USA, focusing on non-emergency care from the providers’ perspective.ResultsRespondents included 105 providers delivering clinical care for individuals with SCD. Areas of practice were most frequently paediatrics (24%) or haematology/SCD specialist (24%). The majority (77%) reported that they were comfortable managing acute pain episodes while 63% expressed comfort with managing chronic pain. Haematologists and SCD specialists showed higher comfort levels prescribing opioids (100% vs 67%, p=0.004) and managing care with hydroxyurea (90% vs 51%, p=0.005) compared with non-haematology providers. Approximately 33% of providers were unaware of the 2014 NHLBI guidelines. Nearly 63% of providers felt patients’ medical needs were addressed while only 22% felt their mental health needs were met.ConclusionsA substantial number of providers did not know about NHLBI’s SCD care guidelines. Barriers to providing care for patients with SCD were influenced by providers’ specialty, training and practice setting. Increasing provider knowledge could improve hydroxyurea utilisation, pain management and mental health support.


2014 ◽  
Vol 61 (7) ◽  
pp. 1252-1256 ◽  
Author(s):  
Rebecca J. Ladd ◽  
Cecelia R. Valrie ◽  
Christy M. Walcott

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 4593-4593
Author(s):  
Andrea R Whitfield ◽  
Julie Kanter

Abstract Background: Low back pain is a very common and costly problem that results in significant morbidity. When patients with sickle cell disease (SCD) present with back pain, physicians often assume that their pain is related to an acute painful crisis or to chronic pain caused by bone infarcts in the spinal column resulting in "H" shaped vertebral bodies. The occurrence of vertebral osteonecrosis in SCD patients is a well-documented cause of back pain and is noted on radiographs and often confirmed on magnetic resonance imaging (MRI). However, as with all presentations of pain in persons with SCD, the etiology can also be non-SCD related and should be fully evaluated. This case series profiles six patients with SCD who presented with back pain and underwent further assessment. Methods: We conducted a retrospective chart review of six patients with SCD (mean age of 30.8 years) who presented with back pain during 2014. Institutional review board (IRB) approval was obtained from the Medical University of South Carolina for retrospective chart review. All of the patients were seen in the Comprehensive Lifespan Sickle Cell Clinic for regular evaluation. These patients underwent further evaluation due to presenting symptoms of increased pain, change in quality or character of pain, or associated neuropathic complaints. Results: Three of the patients who presented with neuropathic symptoms were noted to have other (non-SCD) etiologies of back pain (facet cyst, vertebral disc protrusion) as outlined in Table 2. The etiology of the other three patients who presented with increased frequency of baseline pain was secondary to complications of SCD (Table 1). Table 1. Patients with back pain secondary to SCD complications Patient #1 Patient #2 Patient #3 Age 15yo 25yo 31yo Sex Male Female Female Genotype Hgb SS Hgb SS Hgb SS Body Mass Index (BMI) 27 20 27 Presentation Chronic low back pain (increased symptom for patient on chronic transfusion therapy) Increased frequency of low back pain Increased frequency of back pain MRI findings Diffuse decreased signal intensity of the vertebral bodies, related to iron deposition. Osseous sequelae of SCD with Lincoln log morphology. No evidence of significant degenerative changes. Remodeling of the vertebral bodies consistent with patient's known history of sickle cell disease (hyperplastic marrow). Treatment Ferriprox (on study) Opiates, Cymbalta Opiates Table 2. Patients with back pain secondary to other etiologies Patient #4 Patient #5 Patient #6 Age 32yo 36yo 46yo Sex Female Female Female Genotype Hgb SS Hgb SC Hgb SB+ Body Mass Index (BMI) 30 40 Not recorded Presentation New, atypical low back pain, worse with ambulation and upright position Chronic back pain with numbness and tingling in left leg Chronic low back pain and lower extremity tingling MRI findings Mild facet arthropathy at L3-L4 and L4-S1 with small juxta-articular/facet cysts at L3-4 without neuroforaminal or canal narrowing. Right central disc protrusion at L5-S1 with moderate central canal stenosis contacting the right transiting S1 nerve root. Slight interval increase in posterior disc bulge with bilateral paracentral protrusions and mild bilateral facet hypertrophy at L5-S1 causing mild narrowing of left neural foramen. Treatment Facet block and steroid administration with relief Neuropathic pain medication, physical therapy Neuropathic pain medication, referral for steroid injections Discussion: This case series reveals the importance of full evaluation of pain in patients with SCD, especially in those individuals who present with neuropathic or neurologic causes. These cases demonstrate that other etiologies of back pain can be seen and should be treated in patients with SCD. In addition, there is substantial evidence linking obesity (increased BMI) and incidence of low back pain (as also seen in several of these patients). Thus, enhanced primary care, including attention to obesity and diet, is also imperative in this patient population. Disclosures No relevant conflicts of interest to declare.


Author(s):  
Kristine A. Karkoska ◽  
Kenneth Haber ◽  
Megan Elam ◽  
Sarah Strong ◽  
Patrick T. McGann

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 2969-2969
Author(s):  
Arrey-Takor Ayuk-Arrey ◽  
Isha Darbari ◽  
Allistair Abraham ◽  
Robert Sheppard Nickel

Abstract Background: Hematopoietic stem cell transplant (HSCT) using an HLA-identical sibling donor is a well-established cure for sickle cell disease (SCD). Historically, HSCT was only offered to patients with SCD who had suffered severe complications; however, given improved HSCT outcomes, it is now reasonable to consider HSCT for most patients with SCD who have an HLA-identical sibling. Thus, HLA typing of all full siblings of patients with SCD should be a clinical priority to ensure patients are aware of and have access to this therapeutic option. The primary objectives of this study are to describe the baseline prevalence of HLA typing among a cohort of hospitalized pediatric patients with SCD and to evaluate whether having had HLA typing is associated with certain characteristics. Secondarily, the study describes the acceptability of HLA typing among patients with a healthy (non-SCD) full sibling who had not already had HLA typing at baseline after dedicated outreach to these families. Methods: Between January 1, 2020 and December 31, 2020 a REDCap database of all hospitalized patients with SCD was prospectively maintained. Patient demographic and clinical information was abstracted via retrospective chart review. To evaluate socioeconomic status, a neighborhood area deprivation index (ADI) was determined for each patient using their home address and the Neighborhood Atlas website (https://www.neighborhoodatlas.medicine.wisc.edu/). ADI is a validated ranking (0-100) of Census Block Groups, considering income, education, employment, and housing quality. A higher ADI represents greater socioeconomic disadvantage. As part of a clinical outreach initiative, patients' families who had not already had typing at the time of their hospitalization were contacted to determine if the patient has a healthy full sibling and, if applicable, offer sibling HLA typing. This outreach was originally planned to occur in person at the time of hospitalization or clinic follow-up, but due the COVID-19 pandemic it was paused and when resumed conducted mostly via telephone. Results: During the 52-week study period, 291 patients with SCD were hospitalized at the study pediatric institution. Seventy-one patients (24%) had already completed HLA typing at the time of their first hospitalization during the study period. These patients with HLA typing at baseline were significantly more likely to have a diagnosis of sickle cell anemia (HbSS/HbSβ 0 genotype) and be on disease-modifying therapy (hydroxyurea or chronic transfusion) compared to patients without typing at baseline (Table). Age and sex were not significantly different between patients with and without typing (Table). The group of patients who did not have HLA typing at baseline had a significantly greater ADI (mean 29.7 vs. 24.0, p=.008) and proportion of patients with a high disadvantage ADI score ≥40 (23% vs. 10%, p=.02), Figure. Of the 220 patients with no history of HLA typing, the sibling status of 187 patients was determined via outreach to these families as of July 2021. Among these 187 patients, 81 (43%) reported having a healthy full sibling. Among these 81 patients with siblings, after being offered family HLA typing, 42 (52%) were interested and referred for HLA typing, 29 (36%) were undecided, and 10 (12%) declined typing. Conclusion: Hospitalized pediatric patients with SCD who had already been HLA typed were more likely to have a severe SCD genotype and be on disease-modifying therapy as expected. Patients who had not had HLA typing were more likely to live in a socioeconomically disadvantaged neighborhood. This finding suggests that dedicated outreach to all families regarding HLA typing is needed. Our clinical initiative to offer typing to all hospitalized patients with healthy full siblings was feasible, with a majority of families interested in pursuing HLA typing. Continued work is needed to ensure patients with SCD have equal access to curative therapy regardless of socioeconomic status. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 3794-3794
Author(s):  
Adlette Inati ◽  
Youssef Rachkidi ◽  
Ossama Jradi ◽  
Rabih Wehbe ◽  
Habib Moallem ◽  
...  

Abstract Background: Sickle cell disease (SCD) is one of the most prevalent hemoglobinopathies in Lebanon. Acute stroke, defined as an acute neurological syndrome secondary to arterial occlusion or hemorrhage with resultant neurological symptoms and signs lasting for more than 24 hours, is the most catastrophic brain injury seen in this disorder and has a prevalence of around 10% by 50 years of age. Silent cerebral infarcts (SCI), defined as an abnormal magnetic resonance image (MRI) of the brain and no history of neurologic deficit, are seen in 20–44% of children with sickle cell anemia (SCA) and represent a major risk factor for overt stroke. Identifying asymptomatic patients at high risk of developing sickle-related brain injury helps physicians implement preventive therapies. Aims: Determine prevalence of brain imaging abnormalities in a group of Lebanese patients with SCD and Identify predictive factors for these abnormalities. Methods: A review of brain MRI for 53 SCD patients followed in 2 centers specialized in inherited hemoglobin disorders was undergone. Of those, 42 asymptomatic patients had surveillance brain MRI and 20 had imaging at least twice. T1- and T2- weighted MR imaging at 1.0 T plus FLAIR at 5-mm section thickness were used. All images were read independently by two radiologists with a 10 years experience in neuroradiology. Brain images considered abnormal included atrophy, lacunar infarction, leukoencephalopathy and encephalomalacia. Fisher’s Exact test (Wilcoxon two sample rank-sum test) was employed to study the association of binary data (continuous data) with the 2 groups. The SAS v8.2 (Cary, N.C.) was used to analyze the data. A p-value less than 0.05 was considered significant. Results: Overall stroke prevalence in this group was 34% (18/53). 11 patients (21%), median age 14 years and 6 months, had overt strokes. Of those, 91% had SCA and 9% sickle beta thalassemia (ST). Of the remaining 42 patients, 6 (14%), median age 13 years and 5 months, all having SCA, had MRI findings compatible with SCI. 3 had brain atrophy and 3 encephalomalacia. None of the overt stroke patients had ever received hydroxyurea. As for SCI patients, 5 were on hydroxyurea at imaging time. No one of these 5 had undergone brain imaging prior to hydroxyurea treatment, and it is possible that these SCI are old ones. Bivariate analysis showed an association between the occurrence of overt stroke and premature death (p=0.006), regular blood transfusions (p=0.006), and osteomyelitis (p=0.009). Bivariate analysis showed an association between the occurrence of SCI and presentation of disease before 2 years of age (p=0.053, borderline) and acute chest syndrome (p=0.035). The small number of patients in this group did not allow for multivariate analysis. Conclusion: Stroke prevalence rate in Lebanese SCD patients is lower than reports from others. This may be attributed to the small sample size and to the imaging technology utilized being less sensitive than newer MRI technology. A multicenter Lebanese SCD trial is warranted to assess the true stroke prevalence, the importance of modifying genes and gene-gene interaction in predicting stroke risk, and the efficacy of hydroxyurea for primary stroke prevention.


2012 ◽  
Vol 198 (5) ◽  
pp. 1167-1174 ◽  
Author(s):  
Ali Balci ◽  
Sinem Karazincir ◽  
Yeliz Beyoglu ◽  
Cihangir Cingiz ◽  
Ramazan Davran ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document